Current Report Filing (8-k)
March 13 2017 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 13, 2017
PEREGRINE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-32839
|
|
95-3698422
|
(State of other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
14282 Franklin Avenue, Tustin, California
92780
(Address of Principal Executive Offices)
Registrant’s telephone number, including
area code:
(714) 508-6000
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
o
|
|
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR.14d-2(b))
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
ITEM 2.02 RESULTS
OF OPERATIONS AND FINANCIAL CONDITION
On March 13, 2017, Peregrine
Pharmaceuticals, Inc. (the “Company”) issued a press release to report the Company’s financial results for the
third quarter ended January 31, 2017. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
No additional information is included in this Current Report on Form 8-K.
The information included
in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed “filed” for purposes of, nor
shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of
1934, except as expressly set forth by specific reference in such a filing.
ITEM 7.01 REGULATION
FD DISCLOSURE
On March 13, 2017, at 4:30
p.m. EDT/1:30 p.m. PDT, the Company will host a conference call to discuss its third quarter ended January 31, 2017 financial results.
The webcast of the conference call will be archived on the Company’s website for approximately 30 days.
ITEM 9.01 FINANCIAL
STATEMENTS AND EXHIBITS
(d) Exhibits.
The following material is filed as an exhibit to this Current Report on Form 8-K:
Exhibit
Number
99.1 Press
Release issued March 13, 2017
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
PEREGRINE PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date: March 13, 2017
|
By:
/s/ Paul J. Lytle
|
|
Paul J. Lytle
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
|
|
Number
|
Description
|
|
|
99.1
|
Press Release issued March 13, 2017
|
|
|
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024